Summary
Two individuals with an X-chromosomal deletion were recently found to lack the genes encoding monoamine oxidase type A (MAO-A) and MAO-B. This abnormality was associated with almost total (90%) reductions in the oxidatively deaminated urinary metabolites of the MAO-A substrate, norepinephrine, and with marked (100-fold) increases in an MAO-B substrate, phenylethylamine, confirming systemic functional consequences of the genetic enzyme deficiency. However, urinary concentrations of the deaminated metabolites of dopamine and serotonin (5-HT) were essentially normal. To investigate other deaminating systems besides MAO-A and MAO-B that might produce these metabolites of dopamine and 5-HT, we examined plasma amine oxidase (AO) activity in these two patients and two additional patients with the same X-chromosomal deletion. Normal plasma AO activity was found in all four Norrie disease-deletion patients, in four patients with classic Norrie disease without a chromosomal deletion, and in family members of patients from both groups. Marked plasma amine metabolite abnormalities and essentially absent platelet MAO-B activity were found in all four Norrie disease-deletion patients, but in none of the other subjects in the two comparison groups. These results indicate that plasma AO is encoded by gene(s) independent of those for MAO-A and MAO-B, and raise the possibility that plasma AO, and perhaps the closely related tissue AO, benzylamine oxidase, as well as other atypical AOs or MAOs encoded independently from MAO-A and MAO-B may contribute to the oxidative deamination of dopamine and 5-HT in humans.
Similar content being viewed by others
References
Baker NJ, Adler LW, Waldo M, Gerhardt G, Drebing C, Cox B, Berry S, Phillips W, Freedman R (1988) Reproducibility of the measurement of plasma noradrenergic and dopaminergic metabolites in normal subjects. Psychiatry Res 23: 119–130
Bardsley WG, Crabbe JC, Scott IV (1974) The amine oxidases of human placenta and pregnancy plasma. Biochem J 139: 169–181
Barker R, Boden N, Cayley G, Charlton SC, Henson R, Holmes MC, Kelley ID, Knowles PF (1979) Properties of cupric ions in benzylamine oxidase from pig plasma as studied by magnetic resonance and kinetic methods. Biochem J 177: 289–302
Blaschko H (1974) The natural history of amine oxidases. Rev Physiol Biochem Pharmacol 70: 83–148
Blaschko H, Levine WG (1961) Metabolism of indolealkylamines. In: Rothlin E (ed) Neuropsychopharmacology. Elsevier, Amsterdam, pp 212–243
Bond PA, Cundall RL (1977) Properties of monoamine oxidase in human blood platelets, plasma, lymphocytes and granulocytes. Clin Chim Acta 80: 317–326
Callingham BA (1983) Comparative aspects of monoamine oxidase. Vet Res Commun 7: 325–330
Callingham BA, Barrand MA (1987) Some properties of semicarbazide-sensitive amine oxidases. J Neural Transm [Suppl 23]: 37–54
Cardon PV, Guggenheim FG (1970) Effects of large variations in diet on free catecholamines and their metabolites in urine. J Psychiatry Res 7: 263–273
Clarke DE, Lyles GA, Callingham BA (1982) A comparison of cardiac and vascular clorgyline-resistant amine oxidase and monoamine oxidase. Biochem Pharmacol 31: 27–35
Collins GGS, Sandler M, Williams ED, Youdim MBH (1970) Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225: 817–820
Copeland Es, Campbell IC, Murphy DL (1983) Interaction between cytosolic monoamine oxidase and spin-labeled amphetamine and its modification by clorgyline and pargyline. Biochim Biophys Acta 743: 186–194
Coquil JF, Goridis C, Mack G, Neff NH (1973) Monoamine oxidase in rat arteries: evidence for different forms and selective localization. Br J Pharmacol 48: 590–599
de la Chapelle A, Sankila EM, Lindlof M, Aula P, Norio R (1985) Norrie disease caused by a gene deletion allowing carrier detection and prenatal diagnosis. Clin Genet 28: 317–320
Donnelly CH, Murphy DL (1977) Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26: 853–858
Garrick NA, Murphy DL (1980) Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72: 27–33
Garrick NA, Murphy DL (1982) Monoamine oxidase type A: differences in selectivity towards 1-norepinephrine compared to serotonin. Biochem Pharmacol 31: 4061–4066
Garrick NA, Scheinin M, Chang WH, Linnoila M, Murphy DL (1984) Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem Pharmacol 33: 1423–1427
Hayes BE, Ostrow PT, Clarke CE (1983) Benzylamine oxidase in normal and atherosclerotic human aortae. Exp Mol Pathol 38: 243–254
Karoum F (1983) Mass fragmentography in the analysis of biogenic amines: a clinical, physiological and pharmacological evaluation. In: Parvez S, Nagatsu T, Nagatsu I, Parvez H (eds) Methods in biogenic amine research. Elsevier Science Publishers, Amsterdam, pp 237–255
Karoum F, Nasrallah H, Potkin S, Chuang L, Moyer-Schwing J, Phillips I, Wyatt RJ (1979) Mass fragmentography of phenylethylamine, m- and p-tyramine and related amines in plasma, cerebrospinal fluid, urine, and brain. J Neurochem 33: 201–212
Karoum F, Neff NH (1982) Quantitative gas chromatography-mass spectrometry (GC-MS) of biogenic amines: theory and practice. In: Spector S, Back N (eds) Modern methods in pharmacology. Alan R Liss, New York, pp 39–54
Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37: 333–364
Lan NC, Heinzmann C, Gal A, Klisak I, Orth U, Lai E, Grimsby J, Sparkes RS, Mohandas T, Shih JC (1989) Human monoamine oxidase A and B genes map to Xp11.23 and are deleted in a patient with Norrie disease. Genomics 4: 552–559
Levy ER, Powell JF, Buckle VJ, Hsu YPP, Breakefield XO, Craig IW (1989) Localization of human monoamine oxidase to Xp11.23–11.4 by in situ hybridization: implications for Norrie disease. Genomics 5: 368–370
Lewinsohn R (1981) Amine oxidase in human blood vessels and non-vascular smooth muscle. J Pharm Pharmacol 33: 569–575
Lewinsohn R (1984) Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 17: 223–256
Lewinsohn R, Bohm KH, Glover V, Sandler M (1978) A benzylamine oxidase distinct from monoamine oxidase B: widespread distribution in man and rat. Biochem Pharmacol 27: 1857–1863
Lin AM, Castell CO (1975) Multiple forms of monoamine oxidase in human plasma. Biochem Med 13: 141–156
Lovenberg W, Beaven MA (1971) The release of tritium upon deamination of 3,4-dihydroxy[2-3H]phenylethylamine by plasma amine oxidase. Biochim Biophys Acta 251: 452–455
Lyles GA, Singh I (1985) Vascular smooth muscle cells: a major source of the semicarbazidesensitive amine oxidase of the rat aorta. J Pharm Pharmacol 37: 637–643
Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32: 229–231
Mayanil CSK, Baquer NZ (1984) Comparison of the properties of semipurified mitochondrial and cytosolic oxidases from rat brain. J Neurochem 43: 906–912
McEwen CM (1965 a) Human plasma monoamine oxidase. I. Purification and identification. J Biol Chem 240: 2003–2010
McEwen CM (1965 b) Human plasma monoamine oxidase. II. Kinetic studies. J Biol Chem 240: 2011–2018
McEwen CM (1972) The soluble monoamine oxidase of human plasma and sera. Biochem Psychopharmacol 5: 151–165
McEwen CM, Cohen JD (1963) An amine oxidase in normal human serum. J Lab Clin Med 62: 766–776
Murphy DL (1978) Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem Pharmacol 27: 1889–1893
Murphy DL, Donnelly CH, Richelson E (1976 a) Substrate and inhibitor-related characteristics of monoamine oxidase in C6 rat glial cells. J Neurochem 26: 1231–1235
Murphy DL, Wright C, Buchsbaum M, Nichols A, Costa JL, Wyatt RJ (1976 b) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16: 254–265
Murphy DL, Lipper S, Pickar D, Jimerson D, Cohen RM, Garrick NA, Alterman JS, Campbell IC (1981 a) Selective inhibition of monoamine oxidase type A: clinical antidepressant effects and metabolic changes in man. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. Wiley and Sons, New York, pp 189–205
Murphy DL, Pickar D, Jimerson D, Cohen RM, Garrick NA, Karoum F, Wyatt RJ (1981 b) Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man. In: Usdin E, Dahl SG, Gram LF, Ligjaerde O (eds) Clinical pharmacology in psychiatry: neuroleptic and antidepressant research. MacMillan Publishers, London, pp 307–316
Murphy DL, Sims KB, Karoum F, de la Chapelle A, Norio R, Sankila EM, Breakefield XO (1990) Marked amine and amine metabolite changes in Norrie disease patients with an X chromosomal deletion affecting monoamine oxidase. J Neurochem 54: 242–247
Norqvist A, Fowler CJ, Oreland L (1981) The deamination of monoamines by pig dental pulp. Biochem Pharmacol 30: 403–409
Norrie C (1927) Causes of blindness in children. Acta Ophthalmol 5: 357–386
Ozelius L, Hsu YPP, Bruns G, Powell JF, Chen S, Weyler W, Utterback M, Zucker D, Haines J, Trofatter JA, Conneally PM, Gusella JF, Breakefield XO (1988) Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism. Genomics 3: 53–58
Sandler M (1982) Catecholamine synthesis and metabolism in man: clinical implications (with special reference to Parkinsonism). In: Blaschko H, Muscholl E (eds) Handbook of experimental pharmacology, vol 33. Catecholamines. Springer, Berlin Heidelberg New York, pp 845–899
Sharman DF (1973) The catabolism of catecholamines: recent studies. Br Med Bull 29: 110–115
Shekhar C, Mayanil K, Baquer NZ (1982) Clorgyline and deprenyl insensitive monoamine oxidase in rat brain soluble fraction. Biochem Pharmacol 31: 3925–3927
Siegel S (1956) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York
Sims KB, de la Chapelle A, Norio R, Sankila EM, Hsu YPP, Rinehart WB, Corey TJ, Ozelius L, Powell JF, Bruns G, Gusella JF, Murphy DL, Breakefield XO (1989 a) Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2: 1069–1076
Sims KB, Ozelius L, Corey T, Rinehart WB, Liberfarb R, Haines J, Chen WJ, Norio R, Sankila E, de la Chapelle A, Murphy DL, Gusella J, Breakefield XO (1989 b) Norrie disease gene is near to, but distinct from, the monoamine oxidase genes. Am J Hum Genet 45: 424–434
Tufvesson G (1969) Determination of monoamine oxidase activity in human blood serum with14C-benzylamine and14C-tyramine as substrates. Scand J Clin Lab Invest 25: 71–77
Warburg M (1966) Nome's disease: a congenital progressive oculo-acoustico-cerebral degeneration. Acta Ophthalmol [Suppl 89]: 1–47
Yasunobu KT, Ishizaki H, Minamiura N (1976) The molecular, mechanistic and immunological properties of amine oxidases. Mol Cell Biochem 13: 3–29
Youdim MBH (1972) Multiple forms of mitochondrial monoamine oxidase. Br Med Bull 29: 120–122
Youdim MBH, Holman B (1975) The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. J Neural Transm 37: 11–24
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murphy, D.L., Sims, K.B., Karoum, F. et al. Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J. Neural Transmission 83, 1–12 (1991). https://doi.org/10.1007/BF01244447
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01244447